The Impact of Enhanced Recovery after Surgery Protocol Implementation on Postoperative Pain Management in the Era of Opioid Crisis: The Postchemotherapy Open RPLND Experience.

ERAS RPLND cancer patients enhanced recovery protocol opioids pain retroperitoneal lymph node dissection

Journal

Current cancer drug targets
ISSN: 1873-5576
Titre abrégé: Curr Cancer Drug Targets
Pays: Netherlands
ID NLM: 101094211

Informations de publication

Date de publication:
2023
Historique:
received: 19 06 2022
revised: 03 02 2023
accepted: 16 02 2023
pubmed: 12 5 2023
medline: 12 5 2023
entrez: 12 5 2023
Statut: ppublish

Résumé

Enhanced Recovery After Surgery (ERAS) protocols have been proven to optimize postoperative outcomes; however, misuse of opioid analgesics can still hinder postoperative recovery due to related side effects and potential complications. To determine if the implementation of ERAS protocol in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) patients could help with reducing postoperative pain and opioid use. A case-control study of consecutive testicular cancer patients with indications for PCRLPND, who were offered Conventional Post-operative Management (CPM) or ERAS protocol. Outcomes of interest included Visual Analogue Scale (VAS)-assessed pain level at postoperative days 3, 7, and 30, and Morphine-Equivalent Doses (MEDs)/postoperative day. Intraoperative parameters and postoperative complications were recorded. Parametric and non-parametric tests were used for statistical analysis. In total, 100 opioid-naïve PC-RPLND patients were studied. CPM and ERAS groups (36 and 64 patients, respectively) had similar demographic and baseline clinical characteristics). ERAS group patients had significantly lower blood loss (p = 0.005), blood transfusion rate ( Systematic implementation of ERAS protocol after PC-RPLND improves pain management, optimizes patient recovery, and prevents over-prescription of opioid analgesics.

Identifiants

pubmed: 37170984
pii: CCDT-EPUB-131202
doi: 10.2174/1568009623666230426093255
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

910-916

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Konstantinos Dimitropoulos (K)

Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland, United Kingdom.
Academic Urology Unit, University of Aberdeen, Aberdeen, Scotland, United Kingdom.

Louis L Pisters (LL)

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Christos N Papandreou (CN)

Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Danai Daliani (D)

Department of Medical Oncology, Euroclinic, Athens, Greece.

Anastasios Karatzas (A)

Department of Urology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece.

Argiro Petsiti (A)

Department of Anaesthesiology, University Hospital of Larissa, Larissa, Greece.

Vassilios Tassoudis (V)

Department of Anaesthesiology, University Hospital of Larissa, Larissa, Greece.

Eleni Arnaoutoglou (E)

Department of Anaesthesiology, University Hospital of Larissa, Larissa, Greece.

Panagiotis J Vlachostergios (PJ)

Department of Urology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece.
Department of Medical Oncology, IASO Thessalias Hospital, Larissa, Greece.
Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

Vassilios Tzortzis (V)

Department of Urology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece.

Classifications MeSH